View Older Stories View More Recent Stories

Apr 19, 2022 08:30AM Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Apr 17, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AbbVie and Twitter and Encourages Investors to Contact the Firm
Apr 14, 2022 08:00AM AbbVie to Host First-Quarter 2022 Earnings Conference Call
Apr 14, 2022 05:37AM AbbVie (ABBV) and Genmab (GMAB) Report Topline Results for Epcoritamab from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma
Apr 13, 2022 06:53PM AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 13, 2022 05:26PM Genmab (GMAB) and AbbVie (ABBV) Announce Topline Results for Epcoritamab From Phase 1/2 Trial in Patients with R/R LBCL
Apr 13, 2022 05:26PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 13, 2022 05:25PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 13, 2022 08:00AM BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
Apr 12, 2022 08:03AM AbbVie (ABBV) Reports Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis
Apr 12, 2022 08:00AM AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis
Apr 5, 2022 08:31AM AbbVie (ABBV) and Allergan Report Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age-Rela
Apr 5, 2022 08:30AM Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution) 1.25% in Adults with Age
Apr 4, 2022 12:39PM Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics
Mar 29, 2022 08:00AM AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting
Mar 21, 2022 08:30AM AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
Mar 16, 2022 05:33PM AbbVie (ABBV) Announces FDA Approval of RINVOQ for Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Mar 16, 2022 05:29PM RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Mar 15, 2022 08:45AM Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours
Mar 15, 2022 08:00AM AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
Mar 11, 2022 05:43AM AbbVie (ABBV) and Gideon Richter Collaborate in Neuropsychiatric Diseases
Mar 11, 2022 02:00AM AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
Mar 10, 2022 08:15AM AbbVie (ABBV) Announces Positive Phase 3 Atogepant Data for the Preventive Treatment of Chronic Migraine
Mar 10, 2022 08:15AM AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine
Mar 8, 2022 04:34PM AbbVie (ABBV) Resolves HUMIRA U.S. Litigation with Alvotech
Mar 8, 2022 04:32PM AbbVie Resolves HUMIRA® (adalimumab) U.S. Litigation with Alvotech
Mar 8, 2022 07:32AM Genmab (GMAB) and Abbvie (ABBV) Granted FDA Orphan-Drug Designation to Epcoritamab
Mar 8, 2022 07:31AM Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Mar 8, 2022 07:30AM Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Mar 1, 2022 08:30AM AbbVie to Present at the Cowen 42nd Annual Health Care Conference
Mar 1, 2022 08:01AM AbbVie (ABBV) Acquires Syndesi Therapeutics
Mar 1, 2022 08:00AM AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Feb 28, 2022 04:16PM AbbVie (ABBV) Announces FDA Extended Review Period for SKYRIZI for the Treatment of Moderate to Severe Crohn's Disease in the U.S.
Feb 28, 2022 04:15PM AbbVie Provides Update Regarding SKYRIZI® (risankizumab-rzaa) for the Treatment of Moderate to Severe Crohn's Disease in the U.S.
Feb 28, 2022 08:01AM AbbVie (ABBV) to Seek New Indication for IMBRUVICA in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Feb 28, 2022 08:00AM AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Feb 24, 2022 11:22AM Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting
Feb 24, 2022 08:01AM AbbVie (ABBV) Reports Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
Feb 24, 2022 08:00AM Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
Feb 22, 2022 08:15AM AbbVie (ABBV) Submits sNDA to U.S. FDA for cariprazine for the Adjunctive Treatment of Major Depressive Disorder
Feb 22, 2022 08:15AM AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
Feb 17, 2022 11:33AM AbbVie Declares Quarterly Dividend
Feb 8, 2022 08:01AM AbbVie (ABBV) Announces FDA Approval of JUVEDERM VOLBELLA XC For Undereye Hollows
Feb 8, 2022 08:00AM FDA Approves JUVÉDERM® VOLBELLA® XC For Undereye Hollows
Feb 2, 2022 07:43AM AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
Feb 1, 2022 08:45AM AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO)
Jan 24, 2022 08:00AM Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic (onabotulinumtoxinA)
Jan 21, 2022 04:31PM AbbVie (ABBV) Announces U.S. FDA Approves Second Indication for SKYRIZI to Treat Adults with Active Psoriatic Arthritis
Jan 21, 2022 04:30PM U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
Jan 14, 2022 01:16PM AbbVie (ABBV) Announces FDA Approval of RINVOQ
View More Recent Stories View Older Stories